Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Public ClinicalTrials.gov record NCT02591199. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder Pain Syndrome. The study is randomized and double-blinded such that neither the subject nor doctor will know which drug or placebo is received.
Study identification
- NCT ID
- NCT02591199
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2015 (Type not available)
- Primary completion
- May 14, 2018 (Actual)
- Completion
- Jun 18, 2018 (Actual)
- Last update posted
- Feb 3, 2026
2015 – 2018
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| IC Study, LLC | Escondido | California | 92025 | — |
| University of California San Diego | San Diego | California | 92103 | — |
| Georgia Urology | Cartersville | Georgia | 30120 | — |
| The Urogynecology Center | Overland Park | Kansas | 66209 | — |
| Rutgers Women's Health Clinic | New Brunswick | New Jersey | 08901 | — |
| The Arthur Smith Institue for Urology- North Shore Long Island Jewish Health System | Lake Success | New York | 11042 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27103 | — |
| MetroHealth System, Center for Advanced Gynecology | Cleveland | Ohio | 44109 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Sanford Research | Sioux Falls | South Dakota | 57105 | — |
| Urology of Virginia, PLLC | Virginia Beach | Virginia | 23462 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02591199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02591199 live on ClinicalTrials.gov.